Market Announcement29/09/2026NEUREN PHARMACEUTICALS LIMITEDSecurity Code: NEUPause in TradingTrading in the securities of the entity will be temporarily paused pending a further announcement. ASX Supervision29/09/2026Market Announcement 1/1
Pause in Trading
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Update - Dividend/Distribution - NEU
- Corporate Presentation, 2 September 2026
- Dividend/Distribution - NEU
- Investor presentation, 26 August 2026
- Growing royalty anchors Neuren first ever dividend program
Later from Neuren Pharmaceuticals
- Trofinetide US patent protections extended to March 2041
- FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
- Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals